Targeting the replication stress response in cancer
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Many conventional chemotherapies used in cancer treatment exert their effect by inflicting DNA damage. Highly proliferative tissues, as well as tumour cells, are particularly vulnerable to this damage resulting in unwanted toxicities. In contrast, a targeted therapeutic approach has the aim of specifically eliminating cancer cells but with a reduced effect on healthy tissue. New therapies have been developed that target the replication stress response (RSR), a branch of the broader DNA damage response that specifically deals with interferences of the normal DNA replication program. Different pharmaceutical companies have developed inhibitors of the RSR kinases ATR, CHK1 and WEE1, which are currently at different phases of clinical development. Here, we review how the RSR works at the molecular level, what is the rationale for its targeting, and how we envisage its best use in the clinic, based on patient selection and combination therapies supported by in vitro and in vivo preclinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Causes and consequences of replication stress
Zeman, M. K., & Cimprich, K. A. (2014) · Nature Cell Biology · doi:10.1038/ncb2897 · Cited by 2,079
Schlacher, K., Wu, H., & Jasin, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.015 · Cited by 936
Härtlova, A., Erttmann, S. F., Raffi, F. A., Schmalz, A. M., Resch, U., Anugula, S., Lienenklaus, S., Nilsson, L. M., Kröger, A., Nilsson, J. A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.012 · Cited by 716
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465
Maréchal, A., & Zou, L. (2015) · Cell Research · doi:10.1038/cr.2014.147 · Cited by 465
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13837 · Cited by 382
Hereditary breast and ovarian cancer: new genes in confined pathways
Nielsen, F. C., van Overeem Hansen, T., & Sørensen, C. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.72 · Cited by 367
Combinatorial CRISPR–Cas9 screens for de novo mapping of genetic interactions
Shen, J. P., Zhao, D., Sasik, R., Luebeck, J., Birmingham, A., Bojorquez-Gomez, A., Licon, K., Klepper, K., Pekin, D., Beckett, A. N., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4225 · Cited by 359
Buisson, R., Boisvert, J. L., Benes, C. H., & Zou, L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.029 · Cited by 316
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
DNA damage-induced type I interferon promotes senescence and inhibits stem cell function
Yu, Q., Katlinskaya, Y. V., Carbone, C. J., Zhao, B., Katlinski, K. V., Zheng, H., Guha, M., Li, N., Chen, Q., Yang, T., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.069 · Cited by 260
Mechanisms for initiating cellular DNA replication
Bleichert, F., Botchan, M. R., & Berger, J. M. (2017) · Science · doi:10.1126/science.aah6317 · Cited by 220
Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
Ferrao, P. T., Bukczynska, E. P., Johnstone, R. W., & McArthur, G. A. (2012) · Oncogene · doi:10.1038/onc.2011.358 · Cited by 133
CHK1 as a therapeutic target to bypass chemoresistance in AML
David, L., Fernandez-Vidal, A., Bertoli, S., Grgurevic, S., Lepage, B., Deshaies, D., Prade, N., Cartel, M., Larrue, C., Sarry, J.-E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aac9704 · Cited by 76
MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
Smida, M., Fece de la Cruz, F., Kerzendorfer, C., Uras, I. Z., Mair, B., Mazouzi, A., Suchankova, T., Konopka, T., Katz, A. M., Paz, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13701 · Cited by 44
Research works printed but not linked: 106
- Aarts, 2012, Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1, Cancer Discovery, 2, 524, 10.1158/2159-8290.CD-11-0320 · DOI · Paper page
- Ammazzalorso, 2010, ATR and ATM differently regulate WRN to prevent DSBs at stalled replication forks and promote replication fork recovery, The EMBO Journal, 29, 3156, 10.1038/emboj.2010.205 · DOI · Paper page
- Apte, 2017, Life and cancer without telomerase: ALT and other strategies for making sure ends (don't) meet, Critical Reviews in Biochemistry and Molecular Biology, 52, 57, 10.1080/10409238.2016.1260090 · DOI
- Barlow, 2013, Identification of early replicating fragile sites that contribute to genome instability, Cell, 152, 620, 10.1016/j.cell.2013.01.006 · DOI · Paper page
- Barsanti, 2015, Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors, ACS Medicinal Chemistry Letters, 6, 42, 10.1021/ml500352s · DOI
- Beck, 2010, Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase, The Journal of Cell Biology, 188, 629, 10.1083/jcb.200905059 · DOI · Paper page
- Blackford, 2017, ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response, Molecular Cell, 66, 801, 10.1016/j.molcel.2017.05.015 · DOI · Paper page
- Boguslawski, 1986, Characterization of monoclonal antibody to DNA.RNA and its application to immunodetection of hybrids, Journal of Immunological Methods, 89, 123, 10.1016/0022-1759(86)90040-2 · DOI · Paper page
- Booth, 2013, PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells, Cancer Biology & Therapy, 14, 458, 10.4161/cbt.24424 · DOI
- Bryant, 2014, Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human leukemia and lymphoma cells, Molecular Cancer, 13, 147, 10.1186/1476-4598-13-147 · DOI
- Buisson, 2017, APOBEC3A and APOBEC3B activities render cancer cells susceptible to ATR inhibition, Cancer Research, 77, 4567, 10.1158/0008-5472.CAN-16-3389 · DOI
- Bunting, 2010, 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks, Cell, 141, 243, 10.1016/j.cell.2010.03.012 · DOI · Paper page
- Carette, 2011, Global gene disruption in human cells to assign genes to phenotypes by deep sequencing, Nature Biotechnology, 29, 542, 10.1038/nbt.1857 · DOI · Paper page
- Carrassa, 2012, Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo, Cell Cycle, 11, 2507, 10.4161/cc.20899 · DOI
- Chen, 2015, ATR-mediated phosphorylation of FANCI regulates dormant origin firing in response to replication stress, Molecular Cell, 58, 323, 10.1016/j.molcel.2015.02.031 · DOI · Paper page
- Choi, 2016, ATM mutations in cancer: Therapeutic implications, Molecular Cancer Therapeutics, 15, 1781, 10.1158/1535-7163.MCT-15-0945 · DOI · Paper page
- Couch, 2013, ATR phosphorylates SMARCAL1 to prevent replication fork collapse, Genes & Development, 27, 1610, 10.1101/gad.214080.113 · DOI · Paper page
- D'Angiolella, 2012, Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair, Cell, 149, 1023, 10.1016/j.cell.2012.03.043 · DOI · Paper page
- Davies, 2011, Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation, Cancer Biology & Therapy, 12, 788, 10.4161/cbt.12.9.17673 · DOI
- Davoli, 2017, Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy, Science, 355, 10.1126/science.aaf8399 · DOI · Paper page
- Debatisse, 2012, Common fragile sites: Mechanisms of instability revisited, Trends in Genetics, 28, 22, 10.1016/j.tig.2011.10.003 · DOI · Paper page
- Deeg, 2016, Cancer cells with alternative lengthening of telomeres do not display a general hypersensitivity to ATR inhibition, Frontiers in Oncology, 6, 186, 10.3389/fonc.2016.00186 · DOI
- Dehe, 2017, Control of structure-specific endonucleases to maintain genome stability, Nature Reviews. Molecular Cell Biology, 18, 315, 10.1038/nrm.2016.177 · DOI · Paper page
- Desany, 1998, Recovery from DNA replicational stress is the essential function of the S-phase checkpoint pathway, Genes & Development, 12, 2956, 10.1101/gad.12.18.2956 · DOI · Paper page
- Dillon, 2017, Radiosensitization by the ATR inhibitor AZD6738 through generation of acentric micronuclei, Molecular Cancer Therapeutics, 16, 25, 10.1158/1535-7163.MCT-16-0239 · DOI
- Ding, 2016, Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies, Nature Communications, 7, 12425, 10.1038/ncomms12425 · DOI
- Dungrawala, 2015, The replication checkpoint prevents two types of fork collapse without regulating replisome stability, Molecular Cell, 59, 998, 10.1016/j.molcel.2015.07.030 · DOI · Paper page
- Fellmann, 2017, Cornerstones of CRISPR-Cas in drug discovery and therapy, Nature Reviews. Drug Discovery, 16, 89, 10.1038/nrd.2016.238 · DOI · Paper page
- Flynn, 2015, Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors, Science, 347, 273, 10.1126/science.1257216 · DOI · Paper page
- Fragkos, 2015, DNA replication origin activation in space and time, Nature Reviews. Molecular Cell Biology, 16, 360, 10.1038/nrm4002 · DOI · Paper page
- Gaillard, 2015, Replication stress and cancer, Nature Reviews. Cancer, 15, 276, 10.1038/nrc3916 · DOI · Paper page
- Gilad, 2010, Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner, Cancer Research, 70, 9693, 10.1158/0008-5472.CAN-10-2286 · DOI · Paper page
- Gotwals, 2017, Prospects for combining targeted and conventional cancer therapy with immunotherapy, Nature Reviews. Cancer, 17, 286, 10.1038/nrc.2017.17 · DOI · Paper page
- Green, 2017, Cytosine deaminase APOBEC3A sensitizes leukemia cells to inhibition of the DNA replication checkpoint, Cancer Research, 77, 4579, 10.1158/0008-5472.CAN-16-3394 · DOI
- Groth, 2007, Regulation of replication fork progression through histone supply and demand, Science, 318, 1928, 10.1126/science.1148992 · DOI · Paper page
- Guo, 2015, Interaction of Chk1 with treslin negatively regulates the initiation of chromosomal DNA replication, Molecular Cell, 57, 492, 10.1016/j.molcel.2014.12.003 · DOI
- Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- Harnor, 2017, Targeting DNA-dependent protein kinase for cancer therapy, ChemMedChem, 12, 895, 10.1002/cmdc.201700143 · DOI
- Harrigan, 2011, Replication stress induces 53BP1-containing OPT domains in G1 cells, The Journal of Cell Biology, 193, 97, 10.1083/jcb.201011083 · DOI · Paper page
- Hartford, 2016, Interaction with PALB2 is essential for maintenance of genomic integrity by BRCA2, PLoS Genetics, 12, 10.1371/journal.pgen.1006236 · DOI
- Heald, 1993, Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase, Cell, 74, 463, 10.1016/0092-8674(93)80048-J · DOI · Paper page
- Heijink, 2015, A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity, Proceedings of the National Academy of Sciences of the United States of America, 112, 15160, 10.1073/pnas.1505283112 · DOI · Paper page
- Herrera-Abreu, 2016, Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer, Cancer Research, 76, 2301, 10.1158/0008-5472.CAN-15-0728 · DOI · Paper page
- Hoglund, 2011, Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells, Clinical Cancer Research, 17, 7067, 10.1158/1078-0432.CCR-11-1198 · DOI
- Kadoch, 2013, Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy, Nature Genetics, 45, 592, 10.1038/ng.2628 · DOI · Paper page
- Kim, 2017, Targeting the ATR/CHK1 Axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models, Clinical Cancer Research, 23, 3097, 10.1158/1078-0432.CCR-16-2273 · DOI · Paper page
- Kitagawa, 2004, Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway, Genes & Development, 18, 1423, 10.1101/gad.1200304 · DOI · Paper page
- Krajewska, 2015, ATR inhibition preferentially targets homologous recombination-deficient tumor cells, Oncogene, 34, 3474, 10.1038/onc.2014.276 · DOI
- Kuntz, 2009, The G(2) DNA damage checkpoint: Could this ancient regulator be the Achilles heel of cancer?, Cancer Biology & Therapy, 8, 1433, 10.4161/cbt.8.15.9081 · DOI
- Kwok, 2016, ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells, Blood, 127, 582, 10.1182/blood-2015-05-644872 · DOI · Paper page
- Lachaud, 2016, Ubiquitinated Fancd2 recruits Fan1 to stalled replication forks to prevent genome instability, Science, 351, 846, 10.1126/science.aad5634 · DOI
- Lam, 2014, RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma, Cancer Research, 74, 2193, 10.1158/0008-5472.CAN-13-1703 · DOI · Paper page
- Lam, 2004, Chk1 is haploinsufficient for multiple functions critical to tumor suppression, Cancer Cell, 6, 45, 10.1016/j.ccr.2004.06.015 · DOI · Paper page
- Lecona, 2014, Replication stress and cancer: It takes two to tango, Experimental Cell Research, 329, 26, 10.1016/j.yexcr.2014.09.019 · DOI · Paper page
- Ledermann, 2012, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, The New England Journal of Medicine, 366, 1382, 10.1056/NEJMoa1105535 · DOI · Paper page
- Ledermann, 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, The Lancet Oncology, 15, 852, 10.1016/S1470-2045(14)70228-1 · DOI · Paper page
- Liu, 2010, Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint, Nature, 467, 343, 10.1038/nature09350 · DOI · Paper page
- Lord, 2017, PARP inhibitors: Synthetic lethality in the clinic, Science, 355, 1152, 10.1126/science.aam7344 · DOI · Paper page
- Lossaint, 2013, FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling, Molecular Cell, 51, 678, 10.1016/j.molcel.2013.07.023 · DOI · Paper page
- Lujan, 2016, DNA polymerases divide the labor of genome replication, Trends in Cell Biology, 26, 640, 10.1016/j.tcb.2016.04.012 · DOI · Paper page
- Lukas, 2011, 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress, Nature Cell Biology, 13, 243, 10.1038/ncb2201 · DOI · Paper page
- Macheret, 2015, DNA replication stress as a hallmark of cancer, Annual Review of Pathology, 10, 425, 10.1146/annurev-pathol-012414-040424 · DOI · Paper page
- Mao, 2010, The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage, Cancer Research, 70, 6548, 10.1158/0008-5472.CAN-10-0475 · DOI
- Matthews, 2013, Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies, Expert Opinion on Drug Discovery, 8, 621, 10.1517/17460441.2013.788496 · DOI · Paper page
- Min, 2017, AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells, Molecular Cancer Therapeutics, 16, 566, 10.1158/1535-7163.MCT-16-0378 · DOI
- Mir, 2010, In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma, Cancer Cell, 18, 244, 10.1016/j.ccr.2010.08.011 · DOI · Paper page
- Morgado-Palacin, 2016, Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML, Science Signaling, 9, ra91, 10.1126/scisignal.aad8243 · DOI
- Munoz, 2017, DNA replication stress: From molecular mechanisms to human disease, Chromosoma, 126, 1, 10.1007/s00412-016-0573-x · DOI
- Murga, 2011, Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors, Nature Structural & Molecular Biology, 18, 1331, 10.1038/nsmb.2189 · DOI · Paper page
- Neelsen, 2015, Replication fork reversal in eukaryotes: From dead end to dynamic response, Nature Reviews. Molecular Cell Biology, 16, 207, 10.1038/nrm3935 · DOI · Paper page
- Nieto-Soler, 2016, Efficacy of ATR inhibitors as single agents in Ewing sarcoma, Oncotarget, 7, 58759, 10.18632/oncotarget.11643 · DOI
- O'Connor, 2015, Targeting the DNA damage response in cancer, Molecular Cell, 60, 547, 10.1016/j.molcel.2015.10.040 · DOI · Paper page
- Otto, 2017, Cell cycle proteins as promising targets in cancer therapy, Nature Reviews. Cancer, 17, 93, 10.1038/nrc.2016.138 · DOI · Paper page
- Penna, 2017, Anti-mitotic agents: Are they emerging molecules for cancer treatment?, Pharmacology & Therapeutics, 173, 67, 10.1016/j.pharmthera.2017.02.007 · DOI
- Pfister, 2015, Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation, Cancer Cell, 28, 557, 10.1016/j.ccell.2015.09.015 · DOI · Paper page
- Pommier, 2016, Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action, Science Translational Medicine, 8, 10.1126/scitranslmed.aaf9246 · DOI · Paper page
- PosthumaDeBoer, 2011, WEE1 inhibition sensitizes osteosarcoma to radiotherapy, BMC Cancer, 11, 156, 10.1186/1471-2407-11-156 · DOI
- Prevo, 2012, The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy, Cancer Biology & Therapy, 13, 1072, 10.4161/cbt.21093 · DOI · Paper page
- Ragland, 2013, RNF4 and PLK1 are required for replication fork collapse in ATR-deficient cells, Genes & Development, 27, 2259, 10.1101/gad.223180.113 · DOI · Paper page
- Rajeshkumar, 2011, MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts, Clinical Cancer Research, 17, 2799, 10.1158/1078-0432.CCR-10-2580 · DOI · Paper page
- Ray Chaudhuri, 2016, Replication fork stability confers chemoresistance in BRCA-deficient cells, Nature, 535, 382, 10.1038/nature18325 · DOI · Paper page
- Ruiz, 2016, A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors, Molecular Cell, 62, 307, 10.1016/j.molcel.2016.03.006 · DOI · Paper page
- Russell, 2013, Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma, Cancer Research, 73, 776, 10.1158/0008-5472.CAN-12-2669 · DOI
- Ruzankina, 2007, Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss, Cell Stem Cell, 1, 113, 10.1016/j.stem.2007.03.002 · DOI · Paper page
- Saldivar, 2017, The essential kinase ATR: Ensuring faithful duplication of a challenging genome, Nature Reviews. Molecular Cell Biology, 18, 622, 10.1038/nrm.2017.67 · DOI · Paper page
- Sanjiv, 2016, Cancer-specific synthetic lethality between ATR and CHK1 kinase activities, Cell Reports, 17, 3407, 10.1016/j.celrep.2016.12.031 · DOI
- Santos-Pereira, 2015, R loops: New modulators of genome dynamics and function, Nature Reviews. Genetics, 16, 583, 10.1038/nrg3961 · DOI · Paper page
- Sarmento, 2015, CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress, Oncogene, 34, 2978, 10.1038/onc.2014.248 · DOI
- Schlacher, 2011, Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11, Cell, 145, 529, 10.1016/j.cell.2011.03.041 · DOI · Paper page
- Schoppy, 2012, Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR, The Journal of Clinical Investigation, 122, 241, 10.1172/JCI58928 · DOI · Paper page
- Sen, 2017, Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small cell lung cancer, Clinical Cancer Research, 23, 6239, 10.1158/1078-0432.CCR-17-1284 · DOI · Paper page
- Sen, 2017, CHK1 inhibition in small cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib, Cancer Research, 77, 3870, 10.1158/0008-5472.CAN-16-3409 · DOI · Paper page
- Shaltiel, 2015, The same, only different - DNA damage checkpoints and their reversal throughout the cell cycle, Journal of Cell Science, 128, 607, 10.1242/jcs.163766 · DOI · Paper page
- Shen, 2015, Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells, Cell Reports, 11, 460, 10.1016/j.celrep.2015.03.041 · DOI · Paper page
- Somyajit, 2015, Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart, Nucleic Acids Research, 43, 9835
- Stingele, 2017, Mechanisms of DNA-protein crosslink repair, Nature Reviews. Molecular Cell Biology, 18, 563, 10.1038/nrm.2017.56 · DOI · Paper page
- Techer, 2017, The impact of replication stress on replication dynamics and DNA damage in vertebrate cells, Nature Reviews. Genetics, 18, 535, 10.1038/nrg.2017.46 · DOI · Paper page
- Toledo, 2017, Replication Catastrophe: When a checkpoint fails because of exhaustion, Molecular Cell, 66, 735, 10.1016/j.molcel.2017.05.001 · DOI · Paper page
- Toledo, 2011, Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs, Molecular Oncology, 5, 368, 10.1016/j.molonc.2011.07.002 · DOI · Paper page
- Tsimberidou, 2015, Targeted therapy in cancer, Cancer Chemotherapy and Pharmacology, 76, 1113, 10.1007/s00280-015-2861-1 · DOI · Paper page
- Vendetti, 2015, The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo, Oncotarget, 6, 44289, 10.18632/oncotarget.6247 · DOI · Paper page
- Weisberg, 2015, Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies, Leukemia, 29, 27, 10.1038/leu.2014.149 · DOI
- Wolf, 2016, RPA and Rad51 constitute a cell intrinsic mechanism to protect the cytosol from self DNA, Nature Communications, 7, 11752, 10.1038/ncomms11752 · DOI · Paper page
- Yazinski, 2017, ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells, Genes & Development, 31, 318, 10.1101/gad.290957.116 · DOI · Paper page
- Yin, 2017, Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer, American Journal of Cancer Research, 7, 473
- Zabludoff, 2008, AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies, Molecular Cancer Therapeutics, 7, 2955, 10.1158/1535-7163.MCT-08-0492 · DOI · Paper page
Cited by
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reuterswärd, C., Häkkinen, J., Degasperi, A., Amarante, T. D., Saal, L. H., Hegardt, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0582-4 · Cited by 307
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Pilié, P. G., Gay, C. M., Byers, L. A., O'Connor, M. J., & Yap, T. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0968 · Cited by 330
Self-citationThe plasticity of DNA replication forks in response to clinically relevant genotoxic stress
Berti, M., Cortez, D., & Lopes, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0257-5 · Cited by 329
Metadata
- Authors
- Forment, J. V., & O’Connor, M. J.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 188
- Pages
- 155-167
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2790769350
- Cited by
- 156
- References
- 19
- FWCI
- 6.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.